CRMD - CorMedix, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.6131
+0.0482 (+8.53%)
As of 3:47PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.5649
Open0.5600
Bid0.6067 x 900
Ask0.6100 x 800
Day's Range0.5510 - 0.6149
52 Week Range0.1700 - 0.8000
Volume826,698
Avg. Volume3,621,989
Market Cap52.058M
Beta5.36
PE Ratio (TTM)N/A
EPS (TTM)-0.5480
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE18 days ago

    CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 31, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that NYSE Regulation has accepted the Company's plan to regain compliance with the Exchange's continued listing standards set forth in Sections 1003(a)(i-iii) of the NYSE American Company Guide. CorMedix submitted its plan on July 16, 2018, and has been granted a plan period through December 16, 2019. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2018, CorMedix was notified on June 14, 2018, by the Exchange that the Company was not in compliance with Section 1003(a)(i)-(iii) related to insufficient stockholders' equity.

  • ACCESSWIRE19 days ago

    CorMedix Inc. to Present at The 20th Annual Rodman & Renshaw Global Investment Conference

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 30, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Khoso Baluch, President and Chief Executive Officer, accompanied by Paul Chew, M.D., Chief Medical Officer, will present a corporate overview with a focus on the Company's Neutrolin Phase 3 development program at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018 at the St. Regis New York Hotel in New York City.

  • GlobeNewswire22 days ago

    Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C&J ...

  • Associated Presslast month

    CorMedix: 2Q Earnings Snapshot

    On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 10 cents. The pharmaceutical and medical device company posted revenue of $7,600 in the period. Its adjusted revenue ...

  • ACCESSWIRElast month

    CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update

    - LOCK-IT-100 trial results positive; trial halted for efficacy - Conference Call today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD), ...

  • ACCESSWIRElast month

    CorMedix Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern Time. ...

  • ACCESSWIRE2 months ago

    CorMedix Inc. to Report Second Quarter 2018 Financial Results on Tuesday, August 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 2, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: USANA Health Sciences and CorMedix

    NEW YORK, NY / ACCESSWIRE / July 26, 2018 / It was a day of gains for both USANA Health Sciences Inc. and CorMedix. USANA reported record results for the second quarter while CorMedix announced the Data Safety Monitoring Board's positive review of the interim analysis of data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin. The company can now submit results to the Food & Drug Administration for review.

  • ACCESSWIRE2 months ago

    Cormedix Inc. Announces Positive Results Of Its Neutrolin(R) Phase 3 Lock-It-100 Study Based On Recommendation By Independent Data Safety Monitoring Board

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / July 25, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the interim analysis of the data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin®. Because the pre-specified level of statistical significance was reached and efficacy had been demonstrated, the DSMB recommended the study be terminated early.

  • ACCESSWIRE2 months ago

    Free Research Reports on CorMedix and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Lined up for scanning this morning are the following equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), CorMedix Inc. (NYSE AMER: CRMD), CRISPR Therapeutics AG (NASDAQ: CRSP), and Endocyte Inc. (NASDAQ: ECYT).

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind Chegg, C.H. Robinson Worldwide, Republic Services, CorMedix, Burlington Stores, and Etsy — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chegg, ...

  • ACCESSWIRE3 months ago

    Today's Free Research Reports Coverage on CorMedix and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. This Monday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), Corcept Therapeutics Inc. (NASDAQ: CORT), CorMedix Inc. (NYSE AMER: CRMD), and CRISPR Therapeutics AG (NASDAQ: CRSP).

  • ACCESSWIRE3 months ago

    Cormedix Inc. Completes Review and Source Verification of Phase 3 Lock-It 100 Data For Neutrolin(R)

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / June 20, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed its review and source-verification of the data required for the interim analysis of the Phase 3 LOCK-IT 100 study for Neutrolin®. The Company anticipates the database will be locked shortly and transferred to the independent biostatistician for unblinding and analysis. The independent biostatistician will then provide the results to the Data Safety Monitoring Board (DSMB) for its review, which is expected to occur in July 2018.

  • ACCESSWIRE3 months ago

    Cormedix Inc. Receives a Continued Listing Standard Notice from the NYSE American

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / June 19, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that on June 14, 2018, it received a notice from the NYSE American that, based on its Form 10-Q for the quarter ended March 31, 2018, filed on May 15, 2018, Cormedix does not meet a continued listing standard of the NYSE American as set forth in Part 10 of the NYSE American Company Guide.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! salesforce.com, inc. (NYSE: CRM ) stock was trading ...

  • ACCESSWIRE4 months ago

    CorMedix, Inc. Reports Progress on LOCK- IT 100 Data Review and Appoints Paul Chew as Consultant Advisor CMO

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / May 29, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the Company's clinical operations team has reviewed and source-verified more than 75% of data for the interim analysis of the Phase 3 LOCK-IT 100 study for Neutrolin®. The pace of source verification continues to accelerate, and the Company is on schedule to complete this work by the end of June 2018.

  • With A -26.58% Earnings Drop, Did CorMedix Inc (NYSEMKT:CRMD) Really Underperform?
    Simply Wall St.4 months ago

    With A -26.58% Earnings Drop, Did CorMedix Inc (NYSEMKT:CRMD) Really Underperform?

    When CorMedix Inc’s (AMEX:CRMD) announced its latest earnings (31 March 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I used wereRead More...

  • ACCESSWIRE4 months ago

    Cormedix Inc. Reports First Quarter Financial Results and Provides Business Update

    - Anticipate Data Safety Monitoring Board Review of Interim Analysis in July 2018; Review was Triggered in December 2017 with 28 Confirmed Cases of Catheter-related Bloodstream Infections (CRBSIs) Identified ...

  • ACCESSWIRE4 months ago

    CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / May 9, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE5 months ago

    CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / April 27, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE6 months ago

    CorMedix Inc. Makes NYSE American Section 610(b) Public Announcement

    BEDMINSTER, NJ / ACCESSWIRE / March 20, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment ...

  • ACCESSWIRE6 months ago

    Cormedix Inc. Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update

    Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights : - 28 cases of catheter-related bloodstream infections (CRBSIs) identified by the Clinical Adjudication ...

  • ACCESSWIRE6 months ago

    CorMedix Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / CorMedix Inc. (NYSE American: CRMD ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018 at 4:30:00 PM Eastern ...

  • ACCESSWIRE6 months ago

    CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results on Monday, March 19

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 13, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...